Literature DB >> 12652485

Expression and characterization of a humanized cocaine-binding antibody.

El-Rashdy M Redwan1, Nicholas A Larsen, Bin Zhou, Peter Wirsching, Kim D Janda, Ian A Wilson.   

Abstract

The murine immunoglobulin G (IgG) cocaine-binding monoclonal antibody (mAb), GNC92H2, is notable for its exquisite specificity for cocaine, as opposed to chemically-related cocaine metabolites, and for its moderately high affinity (K(d) approximately 200 nM) for cocaine. Recently, we described the crystal structure of a mouse/human chimeric Fab construct at 2.3 A resolution. Herein, we report the successful framework humanization of a single-chain Fv (scFv) GNC92H2 construct without loss of affinity for cocaine. In brief, we compared the mAb GNC92H2 sequence to human antibody sequences, and used structure-based design to incorporate mutations (total = 49) that would humanize the framework region without affecting the overall shape of the binding pocket or the key cocaine-contact residues. The codons of the rationally designed sequence were optimized for E. coli expression, and the gene was synthesized by a de novo PCR reaction using 14 overlapping primers. Expression of the scFv construct was significantly improved in E. coli by fusion to thioredoxin. Intriguingly, this construct apparently refolds to form soluble active antibody in the reducing environment of the cytoplasm. Competitive ELISA and equilibrium dialysis demonstrated comparable binding activity between the humanized scFv and the whole IgG. The successful humanization of mAb GNC92H2 should enhance its potential therapeutic value by reducing its overall. immunogenicity. Copyright 2003 Wiley Periodicals, Inc. Biotechnol Bioeng 82: 612-618, 2003.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652485     DOI: 10.1002/bit.10598

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  7 in total

1.  Immunopharmacotherapeutic manifolds and modulation of cocaine overdose.

Authors:  Jennifer B Treweek; Amanda J Roberts; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2011-02-26       Impact factor: 3.533

2.  Active immunotherapy for the Treatment of Cocaine Dependence.

Authors:  Berma M Kinsey; Thomas R Kosten; Frank M Orson
Journal:  Drugs Future       Date:  2010-04-01       Impact factor: 0.148

Review 3.  Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users.

Authors:  Stephen Brimijoin
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

4.  AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior.

Authors:  Jonathan B Rosenberg; Martin J Hicks; Bishnu P De; Odelya Pagovich; Esther Frenk; Kim D Janda; Sunmee Wee; George F Koob; Neil R Hackett; Stephen M Kaminsky; Stefan Worgall; Nicole Tignor; Jason G Mezey; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2012-05       Impact factor: 5.695

Review 5.  Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.

Authors:  Amira Y Moreno; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

6.  Molecular cloning and characterization of a single-chain variable fragment antibody specific for benzoylecgonine expressed in Escherichia coli.

Authors:  Kenichiro Mori; Youn Uck Kim
Journal:  J Microbiol       Date:  2008-10-31       Impact factor: 3.422

7.  A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats.

Authors:  Andrew B Norman; Felicia C T Gooden; Michael R Tabet; William J Ball
Journal:  Drug Metab Dispos       Date:  2014-04-14       Impact factor: 3.922

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.